Topics:
Radiation Oncology • Genitourinary Cancers
Can radium-223 be given to prostate cancer patients with a history of visceral metastatic disease?
Can radium-223 be given to patients with progressive diffuse osseous mets if they have a history of visceral mets that resolved with previous treatment? ALYSMPCA excluded these patients, but is a history of visceral mets a contraindication?
Answer from: Radiation Oncologist at Academic Institution
Radium-223 is a bone-targeted radiopharmaceutical. In the ALSYMPCA trial, patients with visceral metastases or lymphadenopathy>3cm were excluded. However, if a patient with mCRPC has visceral disease that resolved with previous treatment, and now has progressive osseous metastases, it would be ve...
Sign in or Register to read more